Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Infection & Immunity-PHAC/CAID/Hep C Res-Psycho/Behav/Epid

University of Calgary

$99,686.00

National Trends in Hepatitis C-Related Hospitalizations, Liver Transplants, Mortality, and Utilization of Antiviral Therapies

FY 2009-10

Summary
Nearly 1 in 100 Canadians have chronic hepatitis C virus (HCV) infection, which may progress to cirrhosis and complications including liver failure, liver cancer, and the need for transplantation. Some studies, predominantly based on mathematical models, suggest that the burden of HCV on the health care system is growing due to aging of the affected population. However, nationwide confirmatory data from Canada is not available. Similarly, although antiviral therapy for chronic HCV (e.g. interferon and ribavirin) is associated with a reduction in complications of the disease, the extent that this therapy is prescribed in Canada, and the association between treatment utilization and complication rates, have not been described. Therefore, in the first part of this study, I propose to use a nationwide Canadian database to identify patients hospitalized for complications of chronic HCV in order to better define changes in disease burden since the 1990s. In the second part of this study, I will use a database that tracks drug prescriptions in Canada to examine the use of and expenditures for anti-HCV therapies since 2003. The extent that these therapies have been utilized will be examined nationally and comparisons made between provinces. Finally, the drug utilization and hospitalization data will be correlated to determine if there is an association between the prescription of antivirals (or lack thereof) and the clinical complications of HCV on a provincial basis. I hypothesize that provinces with low prescription rates for antivirals (adjusted for the size of the population) will have higher rates of hospitalizations for HCV-related complications. This data will prove useful for forecasting future trends in HCV burden for health planning purposes, and identifying disparities in drug utilization that may be targeted in order to reduce the burden of this disease on a nationwide scale.
Program
Catalyst Grant: Infection & Immunity-PHAC/CAID/Hep C Res-Psycho/Behav/Epid
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
198516
Name
Myers Robert P
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Catalyst Grant: Infection and Immunity
Projecttitle
National Trends in Hepatitis C-Related Hospitalizations, Liver Transplants, Mortality, and Utilization of Antiviral Therapies
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$99,686
Cihrequipment2
$0
Programname2
Catalyst Grant: Infection & Immunity-PHAC/CAID/Hep C Res-Psycho/Behav/Epid
Keyworddelim
Cirrhosis; Database; Epidemiology; Health Outcomes Research; Hepatitis C; Interferon
Abstract
Nearly 1 in 100 Canadians have chronic hepatitis C virus (HCV) infection, which may progress to cirrhosis and complications including liver failure, liver cancer, and the need for transplantation. Some studies, predominantly based on mathematical models, suggest that the burden of HCV on the health care system is growing due to aging of the affected population. However, nationwide confirmatory data from Canada is not available. Similarly, although antiviral therapy for chronic HCV (e.g. interferon and ribavirin) is associated with a reduction in complications of the disease, the extent that this therapy is prescribed in Canada, and the association between treatment utilization and complication rates, have not been described. Therefore, in the first part of this study, I propose to use a nationwide Canadian database to identify patients hospitalized for complications of chronic HCV in order to better define changes in disease burden since the 1990s. In the second part of this study, I will use a database that tracks drug prescriptions in Canada to examine the use of and expenditures for anti-HCV therapies since 2003. The extent that these therapies have been utilized will be examined nationally and comparisons made between provinces. Finally, the drug utilization and hospitalization data will be correlated to determine if there is an association between the prescription of antivirals (or lack thereof) and the clinical complications of HCV on a provincial basis. I hypothesize that provinces with low prescription rates for antivirals (adjusted for the size of the population) will have higher rates of hospitalizations for HCV-related complications. This data will prove useful for forecasting future trends in HCV burden for health planning purposes, and identifying disparities in drug utilization that may be targeted in order to reduce the burden of this disease on a nationwide scale.
Competitiondate
200909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Myers, Robert P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,686~ $0~
University of Calgary - $99,686 Grant (2009-10) | Canada Spends